Skip to Content

Press Releases

Press Releases

Jan 08 2018
Intec Pharma Announces Development Collaboration With Global Pharmaceutical Company
JERUSALEM, January 8, 2018 /PRNewswire/ -- Intec Pharma Ltd. (NASDAQ: NTEC) (TASE: NTEC), a clinical stage biopharmaceutical company focused on developing drugs based on its proprietary Accordion Pill™ platform technology, today announced it has entered into a Feasibility and Option agreement with
Jan 03 2018
Intec Pharma Granted Patent in Canada for Accordion Pill™ Carbidopa / Levodopa
JERUSALEM, January 3, 2018 /PRNewswire/ -- Intec Pharma Ltd. (NASDAQ: NTEC) (TASE: NTEC), a clinical-stage biopharmaceutical company focused on developing drugs based on its proprietary Accordion Pill TM  platform technology, today announced that the Canadian Intellectual Property Office has issued
Nov 15 2017
Intec Pharma Reports Third Quarter 2017 Operating and Financial Results
· Closed equity offering of $57.5 million; Cash of $64.7 million at September 30, 2017 · Expanding planned enrollment to 420 patients in its Phase 3 ACCORDANCE Trial; enrollment to be completed in the third quarter of 2018 · Formed new U.S. Medical Affairs and U.S.
Nov 08 2017
Intec Pharma, Ltd. to Present at the Jefferies 2017 London Healthcare Conference
JERUSALEM, November 8, 2017 /PRNewswire/ -- Intec Pharma Ltd. (NASDAQ, TASE: NTEC), a clinical stage biopharmaceutical company focused on developing drugs based on its proprietary Accordion Pill™ platform technology, today announced that Jeffrey Meckler, Chief Executive Officer, will provide a
Nov 01 2017
Intec Pharma Ltd. Announces Changes to its Board of Directors
JERUSALEM, November 1, 2017 /PRNewswire/ -- Intec Pharma Ltd. (Nasdaq, TASE: NTEC), a clinical stage biopharmaceutical company focused on developing drugs based on its proprietary Accordion Pill™ platform technology, today announced that Mr. Zvi Joseph, founder and Mr. Giora Carni, former CEO of
Oct 26 2017
Mr. Linscott brings three decades of broad experience to new role
JERUSALEM, October 26, 2017 /PRNewswire/ -- Intec Pharma Ltd. (Nasdaq: NTEC) (TASE: NTEC), a clinical-stage biopharmaceutical company focused on developing drugs based on its proprietary Accordion Pill™ platform technology, today announced it has named Mr. Walt Linscott to the position of Chief
Oct 06 2017
Intec Pharma to Participate in the Oppenheimer Specialty Pharma Summit
JERUSALEM, October 6, 2017 /PRNewswire/ -- Intec Pharma Ltd. (NASDAQ and TASE: NTEC) today announced that management will participate in the Oppenheimer Specialty Pharma Summit to be held October 11, 2017 at the Sofitel Hotel in New York City. Date:   Wednesday, October 11, 2017 Venue:  Sofitel New
Sep 20 2017
Intec Pharma to Participate in the Ladenburg Thalmann 2017 Healthcare Conference
JERUSALEM, September 20, 2017 /PRNewswire/ -- Intec Pharma Ltd. (NASDAQ and TASE: NTEC) today announced that management will participate in the Ladenburg Thalmann 2017 Healthcare Conference to be held September 26, 2017 at the Sofitel Hotel in New York City.
Sep 08 2017
Intec Pharma to Participate in the 19th Annual Rodman & Renshaw Global Investment Conference
JERUSALEM, September 8, 2017 /PRNewswire/ -- Intec Pharma Ltd. (NASDAQ and TASE: NTEC) today announced that management will participate in the 19th Annual Rodman & Renshaw Global Investment Conference to be held September 10-12, 2017 at the Lotte New York Palace Hotel in New York City.
Sep 01 2017
Intec Pharma to Participate in BioCentury's 24th Annual NewsMakers in the Biotech Industry Conference
JERUSALEM, September 1, 2017 /PRNewswire/ -- Intec Pharma Ltd. (NASDAQ and TASE: NTEC) today announced that management will participate in BioCentury's 24th Annual NewsMakers in the Biotech Industry Conference to be held on September 8, 2017 at the Millennium Broadway Hotel & Conference Center
Displaying 21 - 30 of 74